

		<b>Wednesday, July 30</b>		
6:45 AM	7:45 AM	Continental Breakfast		
7:45 AM	11:00 AM	Retina Surgical Summit (NO CME OR LIVESTREAM)		
		<b>Team Europe:</b> Carl Claes, MD; Carlos Mateo, MD; Marco Mura, MD; Zofia A Nawrocka, MD, PhD; Tom H. Williamson, MD, MBChB, FRCS, FRCOphth	Moderator: Stanislao Rizzo, MD	
		<b>Team of the Americas</b> Martin Charles, MD; Alexandre Grandinetti, MD, PhD; Gabriela Lopezcarasa Hernandez, MD; Virgilio Morales-Canton, MD; Carmen R. Negrin-Martin, MD; Cynthia X. Qian, MD	Moderator: Maria H. Berrocal, MD	
		<b>Team Asia</b> Hussain Ahmad Khaqan, MD; Marie Joan Loy, MD, DPBO, FPAO; Manish Nagpal, MD, FRCS (UK), FASRS; Gavin Tan, MBBS, FRCSEd, FAMS, PhD; Taku Wakabayashi, MD, PhD; Wei-Chi Wu MD, PhD	Moderator: Yusuke Oshima, MD, PhD	
11:00 AM	11:30 AM	Lunch Break		
11:30 AM	12:30 PM	Retina Battle	Moderators: Kourous A Rezaei, MD; David R Chow, MD, FRCS(C)	
		<b>Team 1:</b> Flavio A. Rezende, MD, PhD; Lejla Vajzovic, MD, FASRS; Yoshihiro Yonekawa, MD, FASRS		
		<b>Team 2:</b> Matteo Forlini, MD; Jorge A. Fortun, MD; Aleksandra V. Rachitskaya, MD, FASRS		
		<b>Team 3:</b> Audina M. Berrocal, MD, FASRS; John W. Kitchens, MD; Joel Pearlman, MD, PhD		
12:30 PM	1:30 PM	Retinaws (NO RECORDING)	Moderator: Kourous A Rezaei, MD.	
		<b>Panelists:</b> Maria H Berrocal, MD; Geoffrey G Emerson, MD, PhD, FASRS; Avni P Finn, MD, MBA, FASRS; Sunir J Garg, MD, FACS, FASRS; J Michael Jumper, MD, FASRS; Adrienne W Scott, MD, FASRS; Gaurav K Shah, MD; Christina Y Weng, MD, MBA, FASRS; Charlie C Wykoff, MD, FASRS		
1:30 PM	3:00 PM	Surgical Case Conference		
		<b>Presenters:</b> Sulaiman M Al Sulaiman, MD; Carmen Baumann, MD, PhD, FEBO; Barton Blackorby, MD; Subhendu Boral, MBBS, MD(AIIMS), DNB; Lawrence Chan, MD; Jonathan Chang, MD, FASRS; Geoffrey Emerson, MD, PhD, FASRS; Mallika Goyal, MD; Srinivas Joshi, MD, FASRS; Talia Kaden, MD; Aditya Kelkar, MS, FRCS, FASRS,FRCOphth; Mark McAllister, MD; Sandra Montezuma, MD; Matthew Ohr, MD; Geovanni Rios, MD; Sami Uwaydat, MD; Christina Weng, MD, MBA, FASRS; Zhaotian Zhang, MD	Moderators: Dean Elliott, MD; Prithvi Mruthyunjaya, MD, MHS; Lejla Vajzovic, MD, FASRS	
3:00 PM	3:30 PM	Break		
3:30 PM	5:00 PM	Medical Case Conference		
		<b>Presenters:</b> Nazanin Barzideh, MD, FASRS; Audina M Berrocal, MD FASRS; Andrew Farag, MD; Hong-Uyen Hua, MD; Harsh H Jain, MBBS, DNB; George Jiao, MD; Colin A McCannel, MD; Mohamed R Mohamed, MD; Spencer M Moore, MD, PhD; Kareem Moussa, MD; Robert A Sisk, MD, FACS, FASRS; Bradley T Smith, MD, FASRS; Mudit Tyagi, MS, FASRS; Lejla Vajzovic, MD, FASRS; Rui Wang, MD; Yoshihiro Yonekawa, MD, FASRS; Yuxi Zheng, MD; James L Zimmerman, MD	Moderators: Sruthi Arepalli, MD; Srinivas R Sadda, MD; David Sarraf, MD	
6:00 PM	10:00 PM	Opening Reception: Ballast Point		
		<b>Thursday, July 31</b>		
6:45 AM	7:45 AM	Experience Lab (Fellows & Residents)		
6:45 AM	7:45 AM	Fellowship Directors Breakfast		
8:00 AM	8:05 AM	Opening Comments	Gaurav K Shah, MD	
8:05 AM	8:10 AM	State of Retina	J Michael Jumper, MD, FASRS	
8:10 AM	8:45 AM	Retinal Detachment Symposium 1		
		The Feasibility and Outcomes of Vitrectomy in the Office-Based Operation Room	Taku Wakabayashi, MD, PhD	8:10 AM
		The Use of Incorrect Intraocular Gas Tamponades During Vitreoretinal Surgery	Gaurav K Shah, MD	8:13 AM
		Lincoff vs Artificial Intelligence: A Reappraisal of Lincoff's Rules for Finding the Retinal Tear	John T Thompson, MD	8:16 AM
		Discussion		8:19 AM

		Minimally Invasive Suprachoroidal Buckling Using a Novel Injector: Preclinical Evaluation in Human Cadaver Eyes	Gareth D Mercer, MD, PhD	8:28 AM
		Preoperative OCT Biomarkers of Outer Retinal Alterations in Rhegmatogenous Retinal Detachment: Predictors of Postoperative Visual Outcomes	Eoi Jong EJ Seo, MD, PhD	8:31 AM
		Evaluation of Macular Perfusion Post Rhegmatogenous Retinal Detachment Surgery Using Optical Coherence Tomography Angiography: A Systematic Review and Meta-Analysis	Muhammad Amer R Awan, MD, FRCSEd, FRCOphth, FRCS Glasgow, FACS, FASRS	8:34 AM
		Discussion		8:37 AM
8:45 AM	9:20 AM	<b>Retinal Detachment Symposium 2</b>		
		Risk of Retinal Detachment in Fellow Eye With Lattice Degeneration After Primary Rhegmatogenous Retinal Detachment	Chase A Ludwig, MD, MS	8:45 AM
		Risk of New Retinal Tear or Detachment After Cataract Surgery in Patients With Previously Treated Phakic Retinal Tears	Basil K Williams, MD	8:48 AM
		Predictors of Primary Rhegmatogenous Retinal Detachment Surgical Revision	Ahmed F Shakarchi, MD, MPH	8:51 AM
		Discussion		8:54 AM
		Lyophilized Amniotic Membrane Patches Are a Safe and Effective Treatment for Rhegmatogenous Lesions in Combined Tractional and Rhegmatogenous Retinal Detachment	Angel Garcia, MD	9:02 AM
		Predictors of Primary Anatomic Reattachment With Pneumatic Retinopexy for Rhegmatogenous Retinal Detachment	Aurora Pecaku, MD	9:05 AM
		Comparison of Retinal Detachment Repair Outcomes Using 20% Sulfahexafluoride (SF6) vs Air Tamponade in Pars Plana Vitrectomy Surgery With or Without Scleral Buckle	Trent Chiang, MD, MS	9:08 AM
		Discussion		9:11 AM
9:20 AM	9:41 AM	<b>Case-Based Panel Discussion: Surgery</b>	J. Michael Jumper, MD, FASRS	9:20 AM
9:41 AM	10:01 AM	<b>Invited Talk: What Every Retina Doctor Needs to Know About Neuro-ophthalmology</b>	Andrew G. Lee, MD	9:41 AM
10:01 AM	10:41 AM	<b>Break</b>		10:01 AM
10:41 AM	10:51 AM	<b>Invited Talk: Diabetic Retinopathy: Underappreciated or Overemphasized Managements in 2025</b>	Neil M Bressler MD	10:41 AM
10:51 AM	11:31 AM	<b>Diabetic Retinopathy Symposium 1</b>		
		Volumetric Analysis of Hard Exudates on Optical Coherence Tomography: Biomarker Results of Faricimab vs Aflibercept From Phase 3 YOSEMITE/RHINE	Murtaza K Adam, MD	10:51 AM
		Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the United States	Andres Emanuelli, MD	10:54 AM
		Update on Faricimab for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study	Veeral S Sheth, MD, MBA, FASRS, FACS	10:57 AM
		Discussion		11:00 AM
		Comparability of Diabetic Retinopathy Severity Evaluation on Gold Standard vs Ultra-Widefield Images in YOSEMITE/RHINE Phase 3 Studies	Barbara A Blodi, MD	11:09 AM
		VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema	Yasha S Modi, MD	11:12 AM
		Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema Switching From Other Anti-VEGF Agents	Michael Javaheri, MD	11:15 AM
		Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study	Eric Schneider, MD	11:18 AM
		Discussion		11:21 AM
11:31 AM	12:11 PM	<b>Diabetic Retinopathy Symposium 2</b>		
		Interim Results From the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Diabetic Macular Edema	David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS	11:31 AM

		Impact of PDS in Study Eyes vs Anti-VEGF Injections in Fellow Eyes in Pagoda Trial Patients With Bilateral Diabetic Macular Edema (DME)	Jordan M Graff, MD, FACS	11:34 AM
		A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept or Faricimab, in Diabetic Macular Edema	Jeremiah Brown, MD, MS, FASRS	11:37 AM
		Longitudinal Quantitative Ultra-Widefield Retinal Leakage Assessment in Diabetic Retinopathy Following a Single Axitinib Hydrogel (OTX-TKI) in the HELIOS Trial	Katherine E Talcott, MD	11:40 AM
		Suprachoroidal Avoralstat, a Plasma Kallikrein Inhibitor, Stops Vascular Leakage in a Well-Established Rabbit Model	Dilsher S Dhoot, MD	11:43 AM
		Efficacy and Safety Outcomes over 12 weeks with OCS-01 Eye Drops in DME From DIAMOND-Stage 1 trial: Focus on Subgroup by Prior Treatment Status	Baruch D Kuppermann, MD, PhD, FASRS	11:46 AM
		Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials	Dante Pieramici, MD	11:49 AM
		Discussion		11:52 AM
12:11 PM	12:32 PM	<b>Case-Based Panel Discussion: Diabetic Retinopathy</b>	Charles C Wyckoff, MD, PhD, FASRS	12:11 PM
		<b>Panelists:</b> Andrew J Barkmeier, MD; Jeremiah Brown Jr., MD, MS, FASRS; Matthew A Cunningham, MD, FASRS; Christiana Dinah, BSc. MB BS, MRes; Christopher G Fuller, MD; Roger A Goldberg, MD, MBA		
12:32 PM	1:47 PM	<b>General Lunch + WinR Lunch</b>		12:32 PM
1:47 PM	2:02 PM	<b>Business Meeting</b>		1:47 PM
2:02 PM	2:12 PM	<b>Invited Talk: Future Treatments for Dry Macular Degeneration</b>	David S Boyer, MD	2:02 PM
2:12 PM	2:52 PM	<b>Dry AMD Symposium 1</b>		
		Baseline Characteristics Associated With Geographic Atrophy Progression in the OAKS and DERBY Trials	Srinivas R Sadda, MD	2:12 PM
		Early vs Delayed Pegcetacoplan Treatment for GA Secondary to AMD: 48-Month Results From OAKS, DERBY, and GALE Open-Label Extension	Roger A Goldberg, MD, MBA	2:15 PM
		Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program	Diana V Do, MD, FASRS	2:18 PM
		Discussion		2:21 PM
		Complement Inhibition Treatment for Geographic Atrophy in Eyes With Exudative AMD	Josh O Walsh, MD	2:31 PM
		A Descriptive Analysis of Patients Who Received Pegcetacoplan and Anti-VEGF for the Treatment of Geographic Atrophy and Neovascular AMD	Nimesh A Patel, MD, FASRS	2:34 PM
		Safety Profiles of Combined Anticomplement and Anti-VEGF Intravitreal Therapies for Age-Related Macular Degeneration From Real-World Data	Edward H Wood, MD, FASRS	2:37 PM
		Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections	Ash Pirouz, MD	2:40 PM
		Discussion		2:43 PM
2:52 PM	3:32 PM	<b>Dry AMD Symposium 2</b>		
		The 12-Month Safety Results of the PRIMavera Clinical Trial	Lisa C Olmos de Koo, MD, MBA	2:52 PM
		ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design and Rationale Informed by Outcomes From ARCHER	David A Eichenbaum, MD, FASRS	2:55 PM
		LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration	David S Boyer, MD	2:58 PM
		Discussion		3:01 PM
		Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights From the Phase 3 OAKS and DERBY Trials	Paul Hahn, MD, PhD, FASRS	3:10 PM
		New AREDS Data Analyses on Whether AREDS Patients Should Have Routine Genetic Testing	Stephen R Kaufman, MD	3:13 PM
		Genotype Prediction From Retinal Fundus Images Using Deep Learning in Eyes With Age-Related Macular Degeneration	Glenn C Yiu, MD, PhD	3:16 PM

		Novel Handheld Device for Remote Monitoring of Non-neovascular Age-Related Macular Degeneration and Clinical Validation of Usability and Comfort	Yannis M Paulus, MD	3:19 PM
		Discussion		3:22 PM
3:32 PM	4:12 PM	Break		3:32 PM
4:12 PM	4:42 PM	Macular Pucker - Epiretinal Membrane & Macular Holes Symposium 1		
		First Applications of Digital Surgery in Ophthalmology	Stanislao Rizzo, MD	4:12 PM
		Double Agents of the Vitreous: An <em>En Face</em> OCT Study of Hyalocytes Post Vitrectomy	Richard B Rosen, MD, DSc(Hon), FACS, FASRS, FARVO	4:15 PM
		The Role of Preoperative En Face OCT to Identify Non-internal Limiting Membrane Peeling Candidates for Macular Hole Surgery	Kotaro Tsuboi, MD	4:18 PM
		Large Preretinal Human Amniotic Membrane Graft for Chronic or Persistent Macular Holes	Aristomenis Thanos, MD	4:21 PM
		Long-Term 10-Year Results After the Inverted ILM Flap Technique for Full-Thickness Macular Holes	Zofia Anna A Nawrocka (vel Michalewska), MD, PhD	4:24 PM
		Discussion		4:27 PM
4:42 PM	5:12 PM	Macular Pucker - Epiretinal Membrane & Macular Holes Symposium 2		
		OCT-Angiography (OCTA)-Guided Single-Day Intense Prone Positioning in Macular Hole Surgery	Subhendu Boral, MBBS, MD(AIIMS), DNB	4:42 PM
		Closure Patterns in Macular Holes With Epiretinal Membranes and Correlation With Surgical Technique	Raja Rami P Reddy, MD FRCS FASRS	4:45 PM
		5-Year Functional and Anatomical Outcomes in Eyes With Idiopathic Epiretinal Membranes Following Surgical Removal	Lihteh Wu, MD	4:48 PM
		Hyperacute Epiretinal Membranes After Retinal Detachment Repair: Anatomic Characteristics, Onset, Progression, and Surgical Timing	Vivek Chaturvedi, MD, FASRS	4:51 PM
		Management of Retinal Detachment With Coexisting Macular Hole (MHRD) in the Adult Age Group: Functional and Anatomical Outcome	Pramod S Bhende, MS	4:54 PM
		Discussion		4:57 PM
5:12 PM	5:33 PM	Panel discussion on POD Presentations: Themes by Topics		5:12 PM
5:33 PM	6:33 PM	Scientific Poster Q&A and Exhibit Hall Reception		5:33 PM
		Friday, August 1		
	6:00 AM	STRIDE FOR SIGHT: 5k Run/Walk sponsored by the Foundation of the ASRS		
6:45 AM	7:45 AM	Experience Lab (Fellows & Residents)		
6:45 AM	7:45 AM	International breakfast with presentations		
8:00 AM	8:35 AM	Surgical Techniques Symposium 1		
		Comparison of Traction Force between Current Generation and Next Generation Vitrectomy Systems (25Ga)<span id='_symantecMPKIClientDetector' style='display:none'>_PRESENT</span>	Steve T Charles, MD FASRS FACS FICS	8:00 AM
		Functional Assessment of a Novel 27-Gauge Multi-Spot Laser Probe in a Surgical Simulation Bioniko Eye Model	Kourous A Rezaei, MD	8:03 AM
		The Safety, Brightness and Clinical Options of the LED RGB Light Source on the UNITY Vitreoretinal Cataract System (VCS) Platform	David R Chow, MD, FRCS(C)	8:06 AM
		Discussion		8:09 AM
		Volumetric Evaluation of Novel Single-Step Subretinal Injection Device Using Microscope-Integrated Optical Coherence Tomography	Lejla Vajzovic, MD, FASRS	8:17 AM
		Secondary Scleral-Sutured Toric Intraocular Lens for Astigmatic Correction in the Absence of Capsular Support	Matthew Starr, MD	8:20 AM
		Eight year Outcomes of Pars Plana Vitrectomy and Scleral-Fixated Intraocular Lens Using Gore-Tex Sutures	Luis A Acaba-Berrocal, MD	8:23 AM
		Discussion		8:26 AM
8:35 AM	9:15 AM	Surgical Techniques Symposium 2		

		Postoperative Day 0 as a Substitute for Postoperative Day 1 Examination Following Vitreoretinal Surgery: A Comparative Prospective Study	Christina Y Weng, MD, MBA, FASRS	8:35 AM
		Drop less Vitrectomy with 'Suprachoroidal Trimoxil': A Comparative Analysis of Safety and Efficacy with standard of care topical drops	K. V Chalam, MD, PhD, MBA, FRCS(C), FASRS	8:38 AM
		A Prospective Assessment of the ASRS Surgical Log as a Tool to Accurately Assess Fellow Role and Performance in Surgery	Alexander Melamud, MD, MA	8:41 AM
		Discussion		8:44 AM
		Combined Vitrectomy and Reduced-Dose Transscleral Diode Laser Cyclopexy for Managing Large Cyclodialysis Clefts: A Vitreoretinal Approach	Mauricio Bayram-Suverza, MD	8:53 AM
		Modified Simple Silicone Materials in T-Shaped Macular Buckling Surgery	Yodpong Chantarasorn, MD	8:56 AM
		Visual Outcomes After 1-Stage vs 2-Stage Surgery for Intraocular Foreign Body Removal and Open-Globe Repair, Multicenter Study	Jinghua Chen, MD, PhD	8:59 AM
		Low-Dose Atropine 0.01% Drops for Symptomatic Vitreous Floaters: A Noninvasive, Safe, and Effective Therapeutic Option	Mohsin H Ali, MD	9:02 AM
		Discussion		9:05 AM
9:15 AM	9:50 AM	<b>Surgical Complications Symposium</b>		
		Early Vitrectomy vs Intravitreal Antibiotics Only for Postinjection Endophthalmitis: An IRIS (Intelligent Research in Sight) Registry Report	Andrew C Lin, MD	9:15 AM
		Cataract Surgery Complications in Individuals Who Previously Received Intravitreal Injections	Peter J Kertes, MD, FRCS(C)	9:18 AM
		The Impact of Prefilled Syringe Technology on Rates of Endophthalmitis Following Intravitreal Injection of Faricimab	Philip P Storey, MD, MPH	9:21 AM
		Diagnostic Yield of Diluted Aqueous Fluid Analyzed With Polymerase Chain Reaction Testing in the Workup of Infectious Uveitis	Mariam Mathai, MD	9:24 AM
		Long-Term Visual and Surgical Outcomes in 33 Eyes With Noninfectious Uveitis Requiring Secondary Lens Implantation	Sruthi Arepalli, MD	9:27 AM
Fellows Forum Award Winner		Retinal Complications After Cataract Surgery for Adult Patients With a History of Retinopathy of Prematurity: An IRIS (Intelligent Research in Sight) Registry Analysis	Nikhil Bommakanti, MD	9:30 AM
		Discussion		9:33 AM
9:50 AM	10:30 AM	<b>Break</b>		
10:30 AM	11:00 AM	<b>Wet AMD Symposium 1</b>		
		Baseline and Early Treatment Response Variables Associated With Faricimab Durability in Treatment-Naive nAMD: TENAYA/LUCERNE Post Hoc Analyses	Benjamin Bakall, MD, PhD	10:30 AM
		Rapid Fluid Resolution With Aflibercept 8 mg May Be Associated With Extended Dosing Intervals at Week 96 in nAMD: A PULSAR Post Hoc Analysis	Michael W Stewart, MD	10:33 AM
		PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration	David T Wong, MD, FRCS(C), DRCPSC, FASRS	10:36 AM
		Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in DME and nAMD	Nikolas J London, MD, FACS, FASRS	10:39 AM
		5-Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS	John W Kitchens, MD	10:42 AM
		Discussion		10:45 AM
11:00 AM	11:45 AM	<b>Wet AMD Symposium 2</b>		
		Treatment Burden in Wet Age-related Macular Degeneration Treated with EYP-1901 Versus Aflibercept in the DAVIO 2 Phase 2 Clinical Trial	Avni P Finn, MD, MBA, FASRS	11:00 AM



		Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration	Jennifer I Lim, MD, FARVO, FASRS	11:03 AM
		COAST: A Phase 3 study of intravitreal sozinibercept combined with aflibercept in participants with neovascular age-related macular degeneration	Charles C Wykoff, MD, PhD, FASRS	11:06 AM
		PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results	John A Wells, MD, FACS	11:09 AM
		Vials vs Prefilled Syringes (PFS): Intraocular Pressure (IOP) Spikes From 151,657 Intravitreal Injections (IVIs) From 2010 to 2025 From a Single Center in the United Kingdom	Ian YL Yeung, MA FRCOphth	11:12 AM
		Real-World Intraocular Pressure (IOP) and Glaucoma Outcomes From Intravitreal Treatments Based on Injection Volume	Deepak Sambhara, MD	11:15 AM
		Acute Optic Nerve Anatomic Changes Following Intravitreal Injection of Pharmaceutical Agents	Sami H Uwaydat, MD	11:18 AM
		Swing vs Flick: Assessing Safer Air Bubble Removal Techniques in Intravitreal Injections	Gustavo B Melo, MD, PhD, FASRS	11:21 AM
		Discussion		11:24 AM
11:45 AM	12:15 PM	<b>Wet AMD Symposium 3</b>		
		1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD	Robert L Avery, MD	11:45 AM
		RO-104, a Novel Trispecific Antibody, Significantly Reduces Lesion Area and Vascular Leakage in a Laser-Induced Nonhuman Primate CNV Model	Harit K Bhatt, MD, MBA, FASRS, FACS	11:48 AM
		Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Results From OPTIC and LUNA Trials	Sean D Adrean, MD, FAAO, FASRS	11:51 AM
		Longitudinal Validation of the Performance of an AI-Based Algorithm in a Home OCT Pivotal Study of Age-Related Macular Degeneration	S. Krishna Mukkamala, MD, FASRS	11:54 AM
		The Effect of Baseline Ellipsoid Zone-Area Loss on Treatment Response of Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2	Sophie J Bakri, MD	11:57 AM
		Discussion		12:00 PM
12:15 PM	12:36 PM	<b>Case-Based Panel Discussion: Wet AMD</b>	Christina Y Weng, MD, MBA, FASRS	12:15 PM
12:36 PM	1:07 PM	<b>Awards Ceremony</b>		
		Pyron Award Introduction	Gaurav K. Shah, MD	12:36 PM
		Illuminating the Unknown: Advancing Retinal Science to Restore Vision	Rajendra S Apte, MD, PhD	12:38 PM
		Founders Award Introduction	J Michael Jumper, MD, FASRS	12:43 PM
		The Beauty of Inverted ILM Flap	Jerzy Nawrocki, MD, PhD	12:45 PM
		Young Investigators Award Introduction	Reginald J Sanders, MD	12:50 PM
		“Novel Insights and Future Directions in Rhegmatogenous Retinal Detachment”	Rajeev H Muni, MD, MSC, FRCS(C), FASRS	12:52 PM
		Packo Award Presentation to Kevin J. Blinder, MD, FASRS	J Michael Jumper, MD, FASRS	12:57 PM
		Crystle Apple Award Presentation to Sunil Srivastava, MD	ECS co-Chairs	12:59 PM
		Retina Image Bank Image of the Year	Reginald J Sanders, MD	1:01 PM
		Retina Atlas Chapter of the Year	Retina Atlas Editors	1:02 PM
		2025 M. Gilbert Grand ASRS Vitreoretinal Fellowship Award to Jonathan B Lin, MD, PhD	Reginald J Sanders, MD	1:03 PM
		Retina Hall of Fame Award	John T Thompson, MD	1:05 PM
1:07 PM	2:22 PM	<b>General Lunch + Early Career Section Lunch</b>		
2:22 PM	2:32 PM	<b>Invited Talk: How to Manage Nevi Day to Day for the Vitreoretinal Surgeon</b>	Amy C Scheffler, MD FACS FASRS	
2:32 PM	3:07 PM	<b>Ocular Oncology Symposium</b>		
		Gene Expression Profiling Accurately Predicts Mortality for Medium and Large Uveal Melanoma: Improved Survival Outcomes for Class 1a Greater Than Class 1b Greater Than Class 2	Timothy G Murray, MD, MBA, FASRS	2:32 PM
		Detection of Germline BAP1 Mutations in Patients With Uveal Melanoma	Amy C Scheffler, MD FACS FASRS	2:35 PM

		Independent Validation of a 16-Protein Test to Assess Malignant Potential of Small Uveal Melanocytic Tumors	David A Reichstein, MD	2:38 PM
		Discussion		2:41 PM
		Racial and Ethnic Disparities in Retinoblastoma Treatment Options: A Multi-institutional TriNetX Analysis	Vivienne S Hau, MD, PhD	2:49 PM
		Endodiode Laser With Vitrectomy-Transretinal Biopsy (EDL-VitBx) for Treatment of T1 and T2 Uveal Melanoma: Initial Results of Vision-Sparing, Definitive Local Therapy	Scott C Oliver, MD	2:52 PM
		Retinal Pigment Epithelium Undulations in Primary Vitreoretinal Lymphoma: Hidden Paradox	VISHAL R RAVAL, MBBS, DNB, FMRF, FASRS	2:55 PM
		Discussion		2:58 PM
3:07 PM	3:28 PM	<b>Case-Based Panel Discussion: Ocular Oncology</b>	Moderator: Timothy G. Murray, MD, FASRS	
		Panelists: Ivana K Kim, MD; Scott C Oliver, MD; David A Reichstein, MD; Basil K Williams, MD		
3:28 PM	4:08 PM	<b>Break</b>		
4:08 PM	4:18 PM	<b>Invited Talk: Genetic Testing for the Retina Specialist: What You Need to Know</b>	Aaron Nagiel, MD, PhD	
4:18 PM	4:53 PM	<b>Hereditary Retinal Disease &amp; Genetics Symposium 1</b>		
		Retinal Gene Therapy Surgical Techniques	Robert E MacLaren, DSc DPhil FRCS FRCOphth FACS FMedSci	4:18 PM
		Subretinal Laru-zova Gene Therapy for XLRP: 24-Month Results of the Randomized, Controlled, Multicenter Phase 2 SKYLINE Trial	Robert A Sisk, MD, FACS, FASRS	4:21 PM
		A Novel Modifier Gene Therapy for Retinitis Pigmentosa: 2-Year Results of a Phase 1/2, Multicenter, Dose-Escalation Study of Subretinal OCU400	Syed Shah, MD	4:24 PM
		Discussion		4:27 PM
		Extended Efficacy and Safety of MCO-010 Optogenetic Therapy for RP: 126-Week Results From the RESTORE Follow-Up Study (REMAIN)	David S Liao, MD, PhD	4:35 PM
		Oral Gildeuretinol Slows Disease Progression in Early Stargardt Disease: Updates From the TEASE-3 Study	Kenneth C Fan, MD, MBA	4:38 PM
		Secretion of Ciliary Neurotrophic Factor by NT-501 Encapsulated Cell Technology in Patients With Retinal Degenerative Disorders	Jiong Yan, MD	4:41 PM
		Discussion		4:44 PM
4:53 PM	5:13 PM	<b>Hereditary Retinal Disease &amp; Genetics Symposium 2</b>		
		Key Determinants Influencing Molecular Confirmation After Genetic Testing for Inherited Retinal Dystrophies	Joao Pedro Marques, MD, MSc, PhD, FEBOphth	4:53 PM
		Peripheral Retinal Vessels in Retinitis Pigmentosa	Hossein Ameri, MD, PhD, FRCSI, MRCOphth	4:56 PM
		North Carolina Macular Dystrophy: Haplotype Analysis of 31 Families Shows Single Founders for Each Mutation	Kent W Small, MD, FASRS, FACS	4:59 PM
		Comparison of Retinal Layer Thicknesses After Macular Hole Surgery and Alport Syndrome	Gursel Yilmaz, MD, FEBO, FACS, FASRS	5:02 PM
		Discussion		5:05 PM
5:13 PM	5:31 PM	<b>Pediatric Retina - ROP Symposium</b>		
		P-Score Variability in Retinopathy of Prematurity as a Function of Image View, Capture Time, and Disease Severity	Darius M Moshfeghi, MD, FASRS	5:13 PM
		Evaluating Clinical Signs of Regression in Eyes Treated With Intravitreal Bevacizumab for Type 1 Retinopathy of Prematurity	Yuxi Zheng, MD	5:16 PM
		Familial Exudative Vitreoretinopathy (FEVR): Genotype-Phenotype Associations and Microvascular Abnormalities on Optical Coherence Tomography (OCTA)	Audina M Berrocal, MD FASRS	5:19 PM
		Discussion		5:22 PM
5:31 PM	7:16 PM	<b>WinR Case Conference</b>		

		<b>Saturday, August 2</b>		
<b>6:45 AM</b>	<b>7:45 AM</b>	<b>Experience Lab (Fellows &amp; Residents)</b>		
<b>6:45 AM</b>	<b>7:45 AM</b>	<b>DEI Breakfast</b>		
<b>6:45 AM</b>	<b>7:45 AM</b>	<b>OMIC symposium</b>		
<b>8:00 AM</b>	<b>8:35 AM</b>	<b>Practice Management &amp; Socioeconomics Symposium</b>		
		Accuracy of Initial Anti-VEGF Treatment Selection in Newly Diagnosed Neovascular Age-Related Macular Degeneration: Retina Specialist Choice vs Step Therapy	<b>Prithvi R Bomdica, MD, MBA</b>	8:00 AM
		Economic Impact of Anti-Vascular Endothelial Growth Factor Prior Authorization Process	<b>Ella H Leung, MD</b>	8:03 AM
		Retinal Procedure Volume and Inflation-Adjusted Medicare Reimbursement in the 21st Century	<b>Ron A Adelman, MD, MPH, MBA</b>	8:06 AM
		Discussion		8:09 AM
		Analysis of Antivascular Endothelial Growth Factor Utilization Trends and Prescriber Characteristics Based on Medicare Part B Claims Data: 2017-2022	<b>Stephanie B Engelhard, MD</b>	8:17 AM
		Comparative Cost Analysis of Secondary Intraocular Lens Surgeries Using Time-Driven, Activity-Based Costing	<b>Warren W Pan, MD, PhD</b>	8:20 AM
		Take Out the Trash: Environmental Burden Associated With Intravitreal Injections	<b>Abdullah Abou-Samra, MD</b>	8:23 AM
		Discussion		8:26 AM
<b>8:35 AM</b>	<b>8:45 AM</b>	<b>Invited Talk: Amniotic Membrane in Vitreoretinal Surgery: When and How</b>	<b>Stanislao Rizzo, MD</b>	<b>8:35 AM</b>
<b>8:45 AM</b>	<b>9:25 AM</b>	<b>Retinal Detachment Symposium 3</b>		
		Primary Retinal Detachment Repair in Eyes Deemed High Risk for Proliferative Vitreoretinopathy: Surgical Outcomes in 605 Eyes	<b>M. Ali Khan, MD, FACS, FASRS</b>	8:45 AM
		Interim Report of the FIXER Trial: Prevention of Proliferative Vitreoretinopathy With Intravitreal Methotrexate in Primary Retinal Detachment Repair	<b>Christopher D Riemann, MD</b>	8:48 AM
		Intravitreal Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy in Pediatric Patients	<b>Philip J Ferrone, MD, FASRS</b>	8:51 AM
		Discussion		8:54 AM
		Hypotony Rates After Vitrectomy for PVR: Insights on Intravitreal MTX Use	<b>Mostafa Mafi, MD</b>	9:03 AM
		Encircage and External Drainage to Enhance Vitrectomy Outcomes in Chronic Rhegmatogenous Retinal Detachment with Extensive PVR: A Retrospective Study	<b>Jayant Dr Kumar, MBBS, MS, DNB, MNAMS, FICO, FVRS</b>	9:06 AM
		From Bench to Bedside: Investigating the Use of Netarsudil as a Novel Therapeutic Approach for PVR	<b>Leo A Kim, MD, PhD</b>	9:09 AM
		Postoperative Methotrexate Injections Decrease Reoperation Rate and Improve Vision Following Vitrectomy for PDR and Complex Retinal Detachments	<b>Alan J Franklin, MD, PhD, FASRS</b>	9:12 AM
		Discussion		9:15 AM
<b>9:25 AM</b>	<b>10:05 AM</b>	<b>Retinal Detachment Symposium 4</b>		
		Anatomical and Functional Outcomes of Vitrectomy for the Management of Longstanding Closed Funnel Retinal Detachments: A Single-Center Study	<b>Malek Yassine, MD</b>	9:25 AM
		Assessment of Redetachment Based on Proliferative Vitreoretinopathy Findings on SS-OCT	<b>Isabela Martins Melo, MD</b>	9:28 AM
		Association of Serum Vitamin D Insufficiency With Proliferative Vitreoretinopathy After Rhegmatogenous Retinal Detachment Repair	<b>Steven D Ness, MD</b>	9:31 AM
		Novel Technique of Perfluoro-n-Octane (PFO): Guided Retinectomy Improves Single-Surgery Anatomic Success (SSAS) in Eyes With Proliferative Vitreoretinopathy (PVR)	<b>Ajay E Kuriyan, MD, MS</b>	9:34 AM
		Comparative Cost Analysis of Pediatric and Adult Retinal Detachment Repairs Using Time-Driven, Activity-Based Costing	<b>Nita Valikodath, MD, MS</b>	9:37 AM
		Learning Curve of Scleral Buckling Surgery: The Journey of a Retina Fellow's First 100 Surgeries	<b>Pallavi Priya, MS</b>	9:40 AM



		The Reservoir Technique for Silicone Oil Placement: Intraocular Pressure Control and Long-Term Outcomes	Kathleen R Schildroth, MD	9:43 AM
		Discussion		9:46 AM
10:05 AM	10:15 AM	Invited Talk: OCT Miomarkers for Surgical Retinal Disorders	Srinivas R Sadda, MD	10:05 AM
10:15 AM	10:55 AM	Break		10:15 AM
10:55 AM	11:10 AM	Best of JVRD Panel	Timothy G Murray, MD, MBA, FASRS	10:55 AM
		Panelists: David RP Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS; Carl D Regillo, MD; Steven D Schwartz, MD		
11:10 AM	11:40 AM	Dry AMD Symposium 3		
		Safety and Efficacy of OCU410, a Novel Modifier Gene Therapy, for Treatment of Geographic Atrophy: Phase 1/2 Study Update	Jay Chhablani,	11:10 AM
		Changes in Hyperautofluorescence Area and RPE/Outer Retinal Layer Thickness in the Phase 2a SIGLEC Study Assessing AVD-104 for the Treatment of GA	Carl D Regillo, MD	11:13 AM
		Safety, Tolerability, and Properties of Novel C3 Inhibitor BI-C in Patients With Geographic Atrophy	Brian B Berger, MD	11:16 AM
		Deactivation of CD163+ Retinal Macrophages With AVD-104 Siglec Agonism Can Restore Photoreceptor Function and Vision in Geographic Atrophy	Eleonora M. Lad, MD, PhD	11:19 AM
		Biomarker-Based Efficacy Analysis of Intravitreal CFH Supplementation in a Phase 2 Trial	David M Brown, MD	11:22 AM
		Discussion		11:25 AM
11:40 AM	12:10 PM	Dry AMD Symposium 4		
		A 'Digital Twin' Approach to Modeling Geographic Atrophy Growth	Naresh Mandava, MD	11:40 AM
		Delayed Near-Infrared Analysis (DNIRA) Identifies Novel and Changing Features of Nonexudative (Dry) Age-Related Macular Degeneration (AMD): A Longitudinal Study	Shelley R Boyd, MD, FRCS(C)	11:43 AM
		Vessel density changes in choroid, chorio-capillaries, deep and superficial retinal plexues on OCTA in various stages of ARMD	Prashant K Bawankule, M.S.	11:46 AM
		Retro-Mode (RM): A Newer Insight Into Dry Age-Related Macular Degeneration	SHILPI H NARNAWARE, ICO ( Retina ) , FAICO ( Vitreo-Retina)	11:49 AM
		Elamipretide Protection Against Photoreceptor Loss in Dry AMD: Predictive Baseline Quantitative Ellipsoid Zone Integrity Parameters in ReCLAIM-2	David R. Lally, MD	11:52 AM
		Discussion		11:55 AM
12:10 PM	12:20 PM	PAT Survey and Global Trends Panel		12:10 PM
12:20 PM	1:35 PM	General Lunch + BOR Lunch		12:20 PM
1:35 PM	1:45 PM	Creative Awards		1:35 PM
1:45 PM	2:25 PM	Diabetic Retinopathy Symposium 3		
		Outcomes of Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States Who Were Lost to Follow-up	Rahul N Khurana, MD, FASRS	1:45 PM
		Incidence of Sight-Threatening Pathology Detected by Non-Mydriatic Fundus Photography in a National Diabetic Screening Platform	Shawn C Kavoussi, MD	1:48 PM
		Lower Socioeconomic Status Is Associated With Increased Bevacizumab Use Among Patients Initiating Anti-VEGF Therapy for Diabetic Macular Edema	Judy E Kim, MD, FARVO, FASRS	1:51 PM
		Neighborhood-Level Characteristics Associated With Delay in Surgery and Loss to Follow-up in Tractional Retinal Detachment Due to Proliferative Diabetic Retinopathy	Sally S Ong, MD	1:54 PM
		Diagnosis of Chronic Kidney Disease Using Retinal Imaging and Urine Dipstick Data: A Multimodal Deep Learning Approach	Joonhyung Kim, MD, PhD	1:57 PM
		ChatGPT for Diabetic Retinopathy Screening	Saeed Mohammadi, MD	2:00 PM

		Systemic Biomarkers and Retinal Microvascular Alterations as Noninvasive Indicators of Diabetic Retinopathy and Nephropathy Severity and Diagnosis	Kasra Rezaei, MD	2:03 PM
		Discussion		2:06 PM
2:25 PM	3:05 PM	<b>Diabetic Retinopathy Symposium 4</b>		
		The Association of Pars Plana Vitrectomy With the Progression From Nonproliferative to Proliferative Diabetic Retinopathy	Ahmed B Sallam, MD PhD FRCOphth	2:25 PM
		Mortality Rates Following Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy	Karen M Wai, MD	2:28 PM
		The Risk of Hypoglycemia in Diabetes: An Outcomes-Based Analysis	Shree K Kurup, MD	2:31 PM
		Risk Factors for Diabetic Retinopathy Progression During Pregnancy	Majda Hadziahmetovic, MD	2:34 PM
		Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide	Andrew J Barkmeier, MD	2:37 PM
		Reduced Rates of Diabetic Retinopathy Complications With Use of Continuous Glucose Monitoring: A Multicenter Population-Based Study	Ehsan Rahimy, MD	2:40 PM
		Peripheral Visual Fields in Severe Nonproliferative Diabetic Retinopathy	Jun Kong, MD, PhD	2:43 PM
		Discussion		2:46 PM
3:05 PM	3:40 PM	<b>Retinal Vascular Disease Symposium 1</b>		
		Timing of Ocular Adverse Events in Pooled Analysis of Two Phase 3 Trials of Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2	Dean Elliott, MD	3:05 PM
		A Telemedicine-Enabled Intravenous Thrombolytic Treatment Pathway for Patients With Hyperacute Nonarteritic Central Retinal Artery Occlusion	Robin A Vora, MD	3:08 PM
		Visual Recovery in Patients With Central Retinal Artery Occlusions Treated With Intravenous Thrombolysis	Boback S Modjtahedi, MD	3:11 PM
		The Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Risk of Retinal Vein and Artery Occlusions	Aleksandra V Rachitskaya, MD, FASRS	3:14 PM
		Identification of Risk Factors Associated With Development or Progression of Proliferative Sickle Cell Retinopathy	Adrienne W Scott, MD, FASRS	3:17 PM
		Surgical Outcomes for Proliferative Sickle Cell Retinopathy	Hesham Gabr, MD	3:20 PM
		Discussion		3:23 PM
3:40 PM	4:10 PM	<b>Retinal Vascular Disease 2</b>		
		From Bench to Bedside in CSCR: Discovery of a Rare Genetic Risk Variant and Correlation With In-Human Data Using Faricimab	Elizabeth Rossin, MD, PhD	3:40 PM
		Associations Between Androgen Exposure, PCOS, and Transmasculine Individuals With Central Serous Chorioretinopathy	Danny A Mammo, MD	3:43 PM
		Aflibercept 8 mg in Treatment-Naive Macular Edema Secondary to Retinal Vein Occlusion: Primary Endpoint Results From the QUASAR Study	Seenu M Hariprasad, MD	3:46 PM
		Intracameral Delivery of Bevacizumab in the Management of Anterior Segment Recalcitrant Neovascular Complications of Proliferative Vascular Retinopathies	Marib I Akanda, MD	3:49 PM
		First In-Human Study Using a Novel Suprachoroidal Injector	Yoreh Barak, MD	3:52 PM
		Discussion		3:55 PM
4:10 PM	4:31 PM	<b>Case-Based Discussion: Retinal Vascular Disease</b>	Diana V. Do, MD, FASRS	4:10 PM
7:00 PM	11:59 PM	<b>Closing Reception: The Queen Mary</b>		